Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Trial Profile

A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACTR707 (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 04 Nov 2019 According to an Unum Therapeutics media release, fives clinical sites are active in this study. The company expects to report preliminary data from this study from first cohort patients by the end of this year and expects data from the multiple dose cohort in 2020.
    • 28 Mar 2019 According to an Unum Therapeutics media release, compnay plans to report initial clinical data from the ongoing dose escalation at the end of 2019.
    • 03 Jan 2019 According to an Unum Therapeutics media release, enrollment, dosing and initial clinical data from dose escalation part anticipated in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top